Article: Callisto Announces Report Update from Equity Analyst General Research with Projected Share Price of US$3.00 and Buy Rating.

Article: Callisto Pharmaceuticals Granted Orphan Drug Designation ...
PR Newswire;  September 26, 2006 ;     700+ words ... ... This marks an important step for Callisto's Atiprimod program," commented Callisto Chief Executive Officer Dr. Gary S ... by the FDA for commercialization of Atiprimod, entitles Callisto to seven years of market exclusivity ...

Article: Callisto Pharmaceuticals Redirects Atiprimod ...
Business Wire;  January 27, 2009 ;     700+ words ... ... anticipated for use in RA. Callisto believes that atiprimod holds significant ... 2007 was terminated. Callisto is now discussing atiprimod financing with potential ... clinical results. Callisto has been developing atiprimod to treat severe late ...

Article: Callisto Pharmaceuticals Announces Poster Presentation on ...
Business Wire;  December 1, 2005 ;     700+ words ... ... other abstracts on Callisto's Atiprimod research for high ... blood cancer. Atiprimod has entered Phase ... myeloma patients. Callisto also has drugs ... use and sell Atiprimod and L-Annamycin ... information about Callisto, including recent ...

Article: MD Anderson Cancer Researchers Publish Manuscript on ...
Internet Wire;  July 7, 2005 ;     700+ words ... ... Executive Officer of Callisto Pharmaceuticals. "Atiprimod is currently being ... leukemia, and Atiprimod to treat relapsed multiple myeloma. Callisto intends to initiate ... cardiotoxicity. Callisto's second drug, Atiprimod, is in a Phase ...

Article: Callisto Announces Additional Atiprimod Data from ...
Business Wire;  June 2, 2006 ;     700+ words ... ... IIa trial of Atiprimod specifically to ... warranted." Callisto earlier announced ... trial data of Callisto's drug Atiprimod was published ... use and sell Atiprimod and L-Annamycin ... information about Callisto, including recent ...

Article: Dana-Farber Cancer Researchers Show Callisto ...
Internet Wire;  June 10, 2005 ;     700+ words ... ... a manuscript on Atiprimod, Callisto's drug candidate ... relapsed leukemia, and Atiprimod to treat relapsed multiple myeloma. Callisto intends to initiate ... cardiotoxicity. Callisto's second drug, Atiprimod, is in a Phase ...

Article: Callisto's Drug Atiprimod Active in ...
Business Wire;  October 5, 2005 ;     700+ words ... ... manuscript showing that Atiprimod, Callisto's drug candidate ... relapsed leukemia, and Atiprimod to treat relapsed multiple myeloma. Callisto intends to initiate ... cardiotoxicity. Callisto's second drug, Atiprimod, is in a Phase ...